Coskun, Tamer <br/><br/>
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.  [electronic resource] 

 -  Molecular metabolism  12 2018 
 - 3-14 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2212-8778 
<br/><br/><label>Standard No.: </label>10.1016/j.molmet.2018.09.009  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Animals<br/>Appetite--drug effects<br/>Blood Glucose--metabolism<br/>Body Weight<br/>Diabetes Mellitus, Type 2--drug therapy<br/>Diarrhea--etiology<br/>Female<br/>Gastric Inhibitory Polypeptide--adverse effects<br/>Humans<br/>Hypoglycemic Agents--adverse effects<br/>Incretins--adverse effects<br/>Male<br/>Mice<br/>Mice, Inbred C57BL<br/>Middle Aged<br/>Receptors, Gastrointestinal Hormone--agonists<br/>Vomiting--etiology<br/>Tirzepatide<br/>Glucagon-Like Peptide-1 Receptor Agonists